| Patient | Evel Knievel |
|---|---|
| Date of birth | 1968-10-17 |
| Identifiers | MRN HR-RB001-SYN; SSN (made up) 000-01-4927 |
| Document date | 2026-01-26 |
| Author | Mei-Ling Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Raised transaminases (ALT 88, AST 96 U/L) and platelets of 118 on today's tests, with spider angiomas and palmar erythema, in a 57-year-old retired stunt performer who received many blood transfusions after crashes before 1992, drinks most evenings and has type 2 diabetes. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV and an abdominal ultrasound are ordered. Please see him within three weeks to confirm the cause, stage his liver disease and plan treatment. [S]
Urgency: Within three weeks; sooner if he develops jaundice, ascites, bleeding or confusion. [S]
Questions for the consultant:
Mr. Knievel, 57, is seen at the request of Dr. Rasmussen two weeks after raised transaminases and low platelets were found at his first visit. He received many transfusions after crashes during his stunt career, before blood was screened for hepatitis C. The hepatitis C antibody is positive with HCV RNA 2.35 million IU/mL, genotype 1a; he has never been treated. He drank three or four drinks most evenings and has cut down to about two since the first visit. He has type 2 diabetes on metformin and chronic pain from old fractures; ibuprofen and omeprazole were stopped two weeks ago. He has had no jaundice, abdominal swelling, black stools, vomiting of blood or confusion. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
5 later historical claims are omitted because they describe events after the index age. See the teaching note.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet twice daily with breakfast and supper | Oral route | 2021-03-01 | active | S |
| Ibuprofen 800 mg oral tablet, one tablet three times a day for joint and back pain | One tablet three times a day | Oral route | 2024-06-01 to 2026-01-12 | completed | S |
| Omeprazole 20 mg delayed-release oral capsule, one capsule daily for indigestion from ibuprofen | One capsule daily before breakfast | Oral route | 2024-06-01 to 2026-01-12 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a day | Two tablets up to twice a day as needed; no more than 2 g a day | Oral route | 2026-01-12 | active | S |
| Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day | 4 g to each knee up to four times a day | Topical route | 2026-01-12 | active | S |
| Carvedilol 6.25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-26 to 2026-02-23 | completed | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-26 | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1992 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review ordered | resolved | confirmed | R74.01 | S — Synthetic presenting problem; no symptom or result of his real illness was made public. Superseded at the hepatology consultation. |
| Chronic hepatitis C, genotype 1a, treatment-naive, HCV RNA 2.35 million IU/mL, likely acquired through blood transfusions after crashes; synthetic modern detail linked to his publicly reported transfusion-acquired hepatitis C | active | confirmed | B18.2 | S — Synthetic genotype, viral load and timing; his hepatitis C and its likely transfusion source are documented (D). |
| Compensated cirrhosis from hepatitis C, with alcohol as a cofactor: liver stiffness 26.8 kPa, FIB-4 4.94, nodular liver and a 14.2 cm spleen on ultrasound, platelets 118; Child-Pugh A5, MELD-Na 8; no ascites, encephalopathy, jaundice or bleeding | active | confirmed | K74.69 | S — Synthetic stage of liver disease linked to his documented hepatitis C and later liver transplant. |
| Clinically significant portal hypertension in compensated cirrhosis (liver stiffness 25 kPa or more), treated with carvedilol without screening endoscopy (Baveno VII) | active | confirmed | K76.6 | S — Synthetic finding at the hepatology consultation. |
| Type 2 diabetes on metformin, A1c 7.4% | active | confirmed | E11.65 | S — Synthetic; diabetes is documented only in his last years (D), and placing it at 57 is a synthetic choice. |
| Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioids | active | confirmed | G89.29 | S — Synthetic pain at the index age, anchored to his documented fractures and the pain of his later years. |
Vital signs recorded on 2026-01-26; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 136/82, pulse 78 |
| Skin | Six spider angiomas; palmar erythema; no jaundice |
| Abdomen | Firm liver edge 2 cm below the costal margin; spleen tip palpable; no shifting dullness |
| Neurological | No asterixis |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-26 | Liver stiffness by US.transient elastography | 26.8 | kPa | Below 7 kPa normal; above 12.5 kPa cirrhosis; 25 kPa or more clinically significant portal hypertension | High | S |
| 2026-01-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-01-26 | Total score [AUDIT-C] | 4 | {score} | S | ||
| 2026-01-26 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 6 | {score} | S |
Data reviewed: Dr. Rasmussen's intake note and results: platelets 118, ALT 88, AST 96 U/L, bilirubin 1.1 mg/dL, albumin 3.6 g/dL, INR 1.1, creatinine 0.92 mg/dL, eGFR 97, A1c 7.4%, LDL 112 mg/dL; FIB-4 4.94. Serology: HCV RNA 2.35 million IU/mL, genotype 1a; hepatitis B surface antigen, core antibody and surface antibody negative; hepatitis A IgG negative; HIV negative. Ultrasound a week ago: nodular liver, coarse echotexture, no focal lesion, spleen 14.2 cm, patent portal vein with forward flow, no ascites. Transient elastography in clinic today: 26.8 kPa (reliable), controlled attenuation parameter 248 dB/m. [S]